Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel DiseaseJeffrey S. Hyams, Meena Thayu, William A. Faubion et al.|Gastroenterology|2017Cited by 217
629 Risk of Malignancy in Pediatric Inflammatory Bowel Disease: Results From the DEVELOP RegistryJeffrey S. Hyams, Meena Thayu, Marla Dubinsky et al.|Gastroenterology|2016Cited by 2
Risk of malignancy in paediatric inflammatory bowel disease: results from the DEVELOP registryM Dubinsky, Meena Thayu, Jeffrey Hyams et al.|Journal of Crohns & Colitis|2016Cited by 0